



Amendments to the Claims

1-52 (Currently Cancelled)

53. (New) A compound represented by the following structural formula:




54. (New) A 2-butyne-1,4 dioate, 3-hexyne-2,5-dioate, acetate, acrylate, benzoate, beta-hydroxybutyrate, bisulfate, bisulfite, bromide, caprylate, carbonate, chlorobenzoate, citrate, decanoate, dihydrogenphosphate, formate, fumarate, glycollate, heptanoate, hippurate, hydroxybenzoate, iodide, isobutyrate, lactate, maleate, maleate, malonate, mandelatemetaphosphate, methanesulfonate, methoxybenzoate, mono-hydrogenphosphate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, oxalate, para-toluenesulfonate, para-bromophenylsulfonate, phenylacetate, phenylbutyrate, phenylpropionate, phosphate, phthalate, propanesulfonate, propiolate, propionate, pyrophosphate, pyrosulfate, sebacate, suberate, succinate, sulfate, sulfite, tartrate or xylenesulfonate salt of a compound represented by the following structural formula:



55. (New) A pharmaceutical formulation comprising the compound of claim 53 and one or more pharmaceutically acceptable carriers, excipients or diluents.

- 56. (New) A pharmaceutical formulation comprising a salt of claim 54 and one or more pharmaceutically acceptable carriers, excipients or diluents or
- 57. (New) A method for treating obesity which comprises administering the compound of claim 53 to a patient in need thereof.
- 58. (New) A method for treating obesity which comprises administering a salt of claim 54 to a patient in need thereof.
- 59. (New) The method of claim 57 wherein the patient is a human.
- 60. (New) The method of claim 58 wherein the patient is a human.
- 61. (New) A method for treating Type II diabetes which comprises administering the compound of claim 53 to a patient in need thereof.
- 62. (New) A method for treating Type II diabetes which comprises administering a salt of claim 54 to a patient in need thereof.
- 63. (New) The method of claim 61 wherein the patient is a human.
- 64. (New) The method of claim 62 wherein the patient is a human.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "G. T. Voy", written in a cursive style.

Gilbert T. Voy
Attorney for Applicants
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division/GTV
Lilly Corporate Center
Indianapolis, Indiana 46285

October 25, 2003